SynthesisClinical and molecular hepatology2024
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis.
Synthesis in Clinical and molecular hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 5 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- [Construction norms for the tiered diagnosis and treatment and standardized management center of metabolic-associated fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Guideline
- Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework.Cancer medicine · 2025Pooled it
- Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.Hepatology international · 2024Pooled it
- APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.Hepatology international · 2024Guideline
- Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.BMC endocrine disorders · 2024Pooled it
- Epidemiological and socio-economic burden of MASH (previously known as NASH) in Europe: a systematic literature review.Journal of endocrinological investigation · 2026Review
- Article
- Construction and Validation of a TyG-ALT-Based Diagnostic Risk-Stratification Model for Metabolic-Associated Fatty Liver Disease in Patients with Obstructive Sleep Apnea.Journal of clinical medicine · 2026Article
- Integrated Plasma and Tissue Lipid Profiling Demonstrates a Distinctive Metabolic Profile in MAFLD-Associated Non-Cirrhotic Hepatocellular Carcinoma.International journal of molecular sciences · 2026Article
- Hepatocellular carcinoma surveillance-is it time to update clinical practice?Hepatobiliary surgery and nutrition · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach.The Kaohsiung journal of medical sciences · 2026Review
- Integrating machine learning and spatial transcriptomics uncovers shared immunomodulatory deubiquitinases in MAFLD and HCC.Human genetics · 2026Article
- Noncanonical function of epigenetic reader YTHDF1 inhibits MASLD progression by maintaining peroxisomes and mitochondrial homeostasis.Experimental & molecular medicine · 2026Article
- Comparison of patients with HCC with and without MASLD after surgical resection.JHEP reports : innovation in hepatology · 2026Article
- Integrative Multiomics Analysis Reveals the Ameliorative Effects ofMolecules (Basel, Switzerland) · 2026Article
- Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection.World journal of gastroenterology · 2026Review
- Comparison of the efficacy of transarterial chemoembolization combined with radiofrequency ablation or sintilimab and bevacizumab for unresectable hepatocellular carcinoma.BMC gastroenterology · 2026Article
- Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study.Scientific reports · 2026Article
- Mechanistic roles and intervention strategies involving gut microbiota, amino acid metabolism, and the tumor immune microenvironment in MAFLD-HCC progression.Clinical and experimental medicine · 2025Review
- Rewriting the MASLD-associated hepatocellular carcinoma script: Targeting epigenetics and metabolism.International journal of cancer · 2025Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 9 institutions in 6 countries.
Funding
Abstract
BACKGROUND/
aimsThe global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis plus defined markers of metabolic dysfunction, irrespective of concurrent liver disease. We aimed to determine the total global prevalence of MAFLD in HCC cohorts (total-MAFLD), including the proportion with MAFLD as their sole liver disease (single-MAFLD), and the proportion of those with concurrent liver disease where MAFLD was a contributary factor (mixed-MAFLD).
methodsThis systematic review and meta-analysis included studies systematically ascertaining MAFLD in HCC cohorts, defined using international expert panel criteria including ethnicity-specific BMI cut-offs. A comparison of clinical and tumour characteristics was performed between single-MAFLD, mixed-MAFLD, and non-MAFLD HCC.
results22 studies (56,565 individuals with HCC) were included. Total and single-MAFLD HCC prevalence was 48.7% (95% confidence interval [CI] 34.5-63.0%) and 12.4% (95% CI 8.3-17.3%), respectively. In HCC due to chronic hepatitis B, C, and alcohol-related liver disease, mixed-MAFLD prevalence was 40.0% (95% CI 30.2-50.3%), 54.1% (95% CI 40.4-67.6%) and 64.3% (95% CI 52.7-75.0%), respectively. Mixed-MAFLD HCC had significantly higher likelihood of cirrhosis and lower likelihood of metastatic spread compared to single-MAFLD HCC, and a higher platelet count and lower likelihood of macrovascular invasion compared to non-MAFLD HCC.
conclusionMAFLD is common as a sole aetiology, but more so as a co-factor in mixed-aetiology HCC, supporting the use of positive diagnostic criteria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.